Kura Oncology’s (KURA) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Thursday morning,Benzinga reports.

Other analysts also recently issued reports about the company. UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. JMP Securities restated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday. Finally, Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Stock Performance

Kura Oncology stock traded up $0.92 during midday trading on Thursday, hitting $10.98. 2,521,641 shares of the company’s stock were exchanged, compared to its average volume of 974,485. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $853.85 million, a price-to-earnings ratio of -4.63 and a beta of 0.86. Kura Oncology has a 12-month low of $9.06 and a 12-month high of $24.17. The firm’s 50 day simple moving average is $18.28 and its 200 day simple moving average is $19.82.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Kura Oncology during the 1st quarter worth $110,000. ProShare Advisors LLC raised its position in Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after acquiring an additional 1,588 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after purchasing an additional 28,212 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Kura Oncology by 17.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after purchasing an additional 2,940 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.